Abstract
Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy
Current Drug Targets
Title: Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
Volume: 10 Issue: 2
Author(s): U. Elsasser-Beile, P. Buhler and P. Wolf
Affiliation:
Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy
Abstract: Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
Export Options
About this article
Cite this article as:
Elsasser-Beile U., Buhler P. and Wolf P., Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354601
DOI https://dx.doi.org/10.2174/138945009787354601 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Recent Advances of Novel Therapeutic Agents from Botanicals for Prevention and Therapy of Breast Cancer: An Updated Review
Current Cancer Therapy Reviews Cisplatin Resistance and Transcription Factors
Current Medicinal Chemistry - Anti-Cancer Agents The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Editorial: The microRNA 221/222 Cluster: Inaugurating a New Era in Cardiovascular Disease and Cancer?
Current Vascular Pharmacology Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Current Pharmaceutical Design The Activity of Titanocene T Against Xenografted Caki-1 Tumors
Letters in Drug Design & Discovery Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?
Current Cancer Drug Targets Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Bioactivity of Hybrid Polymeric Magnetic Nanoparticles and Their Applications in Drug Delivery
Current Pharmaceutical Design Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Inhibitory Effect of Artemisinin on Testosterone Propionate Induced Benign Prostatic Hyperplasia
Current Drug Discovery Technologies Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry